VERU Share Price Performance
US$2.34
-4.51 (-65.82%)
88.2% undervalued intrinsic discount
US$19.75
Fair Value
Price US$2.34
AnalystConsensusTarget US$19.75
AnalystHighTarget US$30.00
Fair ValueUS$19.75
Share Pricen/a
Veru Inc. Stock Price
- 2 Narratives written by author
- 0 Comments on narratives written by author
- 18 Fair Values set on narratives written by author
VERU Community Narratives
AN
Fair Value US$19.75 88.2% undervalued intrinsic discount
Aging Trends And FDA Clarity Will Unlock Opportunity
0users have liked this narrative
0users have commented on this narrative
13users have followed this narrative
AN
Fair Value US$30 92.2% undervalued intrinsic discount
GLP-1 Lean Mass Preservation Will Drive Powerful Long-Term Upside Potential
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
GLP-1 Lean Mass Preservation Will Drive Powerful Long-Term Upside Potential
Catalysts About Veru Veru is a late clinical stage biopharmaceutical company developing novel oral medicines for cardiometabolic and inflammatory diseases, with a lead focus on chronic weight management. What are the underlying business or industry changes driving this perspective?Read more
28
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$30
92.2% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
47.18% p.a.
Profit Margin
20.88%
Future PE
47.97x
Price in 2028
US$36.71
Aging Trends And FDA Clarity Will Unlock Opportunity
Key Takeaways Innovative therapy and robust patent protection position Veru to capture strong, long-term growth in the expanding obesity and chronic disease market. Advancing clinical progress, regulatory clarity, and potential strategic partnerships could accelerate commercialization and improve earnings visibility while reducing funding risks.Read more
86
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
13users have followed this narrative
AN
US$19.75
88.2% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
23.17% p.a.
Profit Margin
23.22%
Future PE
45.94x
Price in 2028
US$22.92
Trending Discussion
Recently Updated Narratives
AN
GLP-1 Lean Mass Preservation Will Drive Powerful Long-Term Upside Potential
Fair Value: US$30 92.2% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Aging Trends And FDA Clarity Will Unlock Opportunity
Fair Value: US$19.75 88.2% undervalued intrinsic discount
13 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Veru Inc. Key Details
About VERU
- Founded
- 1971
- Employees
- 20
- CEO
- WebsiteView website
Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS) in Florida and internationally. It provides FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company develops enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, an oral selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.
